APOGEE THERAPEUTICS Buyout Closes as Shares Head for Delisting

An 8-K filing shows Apogee Therapeutics has completed a change-of-control transaction, replaced its board and recapitalized to just 1,000 shares.

Share
Apogee Therapeutics develops antibody therapies for inflammatory and immunology diseases.
Apogee Therapeutics develops antibody therapies for inflammatory and immunology diseases. Foto: Louis Reed via Unsplash